H Barton Grossman
Overview
Explore the profile of H Barton Grossman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
204
Citations
7316
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bree K, Hensley P, Lobo N, Brooks N, Nogueras-Gonzalez G, Guo C, et al.
J Urol
. 2022 Jun;
208(2):284-291.
PMID: 35770498
Purpose: There is variation amongst guidelines with respect to risk stratification of Ta tumors, specifically high-grade (HG) Ta tumors. We sought to investigate the response of all Ta tumors to...
2.
Bree K, Hensley P, Lobo N, Brooks N, Nogueras-Gonzalez G, Guo C, et al.
J Urol
. 2022 Jun;
208(2):290-291.
PMID: 35770497
No abstract available.
3.
Hensley P, Bree K, Brooks N, Matulay J, Li R, Nogueras-Gonzalez G, et al.
Eur Urol Oncol
. 2021 May;
5(3):347-356.
PMID: 33935020
Background: Guideline indications for restaging transurethral resection (reTUR) for high-grade (HG) Ta bladder tumors vary due to a paucity of data. Objective: To investigate guideline-based, risk-adapted approaches to reTUR for...
4.
Matulay J, Li R, Hensley P, Brooks N, Narayan V, Grossman H, et al.
J Urol
. 2021 Mar;
205(6):1620-1621.
PMID: 33734859
No abstract available.
5.
Matulay J, Li R, Hensley P, Brooks N, Narayan V, Grossman H, et al.
J Urol
. 2021 Jan;
205(6):1612-1621.
PMID: 33502236
Purpose: Recurrent disease after bacillus Calmette-Guérin treatment presents a therapeutic challenge. To aid trial development, the U.S. Food and Drug Administration defined "adequate bacillus Calmette-Guérin" therapy and adopted the "bacillus...
6.
Brooks N, Kokorovic A, Xiao L, Matulay J, Li R, Ranasinghe W, et al.
BJU Int
. 2020 Nov;
128(1):65-71.
PMID: 33210440
Objectives: To evaluate if the obesity paradox, wherein obesity portends worse overall prognosis for a disease but improved outcomes for patients receiving immunotherapy, exists for patients receiving bacillus Calmette-Guérin (BCG)...
7.
Grossman H, Bellmunt J, Black P
Eur Urol Oncol
. 2019 Jul;
2(5):597-602.
PMID: 31279815
Current guidelines recommend cisplatin-based neoadjuvant chemotherapy prior to radical cystectomy as the preferred treatment of muscle-invasive bladder cancer. Nevertheless, for multiple reasons compliance with this guideline recommendation is low. This...
8.
Li R, Metcalfe M, Tabayoyong W, Guo C, Nogueras Gonzalez G, Navai N, et al.
Eur Urol Oncol
. 2019 Jun;
2(3):286-293.
PMID: 31200843
Background: Tumors that recur after bacillus Calmette-Guerin (BCG) therapy are considered to be of very high risk, and patients are often recommended to undergo radical cystectomy (RC). However, the nuances...
9.
Guo C, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, et al.
Cell Rep
. 2019 May;
27(6):1781-1793.e4.
PMID: 31067463
Sarcomatoid urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARC and...
10.
Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee J, et al.
Cell Rep
. 2019 Feb;
26(8):2241-2256.e4.
PMID: 30784602
We used whole-organ mapping to study the locoregional molecular changes in a human bladder containing multifocal cancer. Widespread DNA methylation changes were identified in the entire mucosa, representing the initial...